Wells Fargo & Company Tempest Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TPST
# of Institutions
28Shares Held
1.72MCall Options Held
30KPut Options Held
80.5K-
Black Rock Inc. New York, NY550KShares$682,2980.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA176KShares$218,4790.0% of portfolio
-
Geode Capital Management, LLC Boston, MA154KShares$191,2580.0% of portfolio
-
Fil LTD Hamilton, D0130KShares$160,6770.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX106KShares$130,9440.09% of portfolio
About Tempest Therapeutics, Inc.
- Ticker TPST
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 10,418,900
- Market Cap $12.9M
- Description
- Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...